Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tuomai Medical, has received a medical device registration certificate from the National Medical Products Administration for a polyethylene glycol embolization microsphere, marking a significant advancement in the company's interventional oncology product line [1] Group 1 - The registration certificate number is Guo Xie Zhu Ren 20263130187, valid from January 28, 2026, to January 27, 2031 [1] - The product is classified as a Class III medical device, intended for embolization treatment of hypervascular malignant tumors in solid organs [1] - This product represents the company's first embolization product in the field of tumor interventional therapy, potentially offering improved treatment options [1] Group 2 - The product must obtain a production license before it can be sold, and the sales situation remains uncertain, making it difficult to predict its impact on revenue [1]

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The subsidiary involved in this development is Shanghai Tuomai Medical Technology Co., Ltd. [1]

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

2月2日，心脉医疗跌2.87%，成交额1.54亿元。两融数据显示，当日心脉医疗获融资买入额2089.34万 元，融资偿还1189.32万元，融资净买入900.02万元。截至2月2日，心脉医疗融资融券余额合计4.82亿 元。 机构持仓方面，截止2025年9月30日，心脉医疗十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股253.79万股，相比上期增加178.03万股。华宝中证医疗ETF（512170）位居第三大流通股 东，持股211.50万股，相比上期减少30.12万股。南方中证1000ETF（512100）位居第六大流通股东，持 股67.64万股，相比上期减少1.98万股。博时上证科创板100ETF联接A（019857）退出十大流通股东之 列。 融资方面，心脉医疗当日融资买入2089.34万元。当前融资余额4.79亿元，占流通市值的4.21%，融资余 额低于近一年20%分位水平，处于低位。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina ...

资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 1月29日的资金流向数据方面，主力资金净流出1249.57万元，占总成交额6.11%，游资资金净流入 551.61万元，占总成交额2.7%，散户资金净流入697.96万元，占总成交额3.41%。 心脉医疗2025年三季报显示，前三季度公司主营收入10.15亿元，同比上升4.66%；归母净利润4.29亿 元，同比下降22.46%；扣非净利润3.72亿元，同比下降25.8%；其中2025年第三季度，公司单季度主营 收入3.0亿元，同比上升64.68%；单季度归母净利润1.14亿元，同比下降23.63%；单季度扣非净利润1.02 亿元，同比下降11.84%；负债率15.85%，投资收益1160.33万元，财务费用-785.84万元，毛利率 70.4 ...

证券之星消息，截至2026年1月28日收盘，心脉医疗(688016)报收于94.0元，下跌1.67%，换手率 1.29%，成交量1.59万手，成交额1.5亿元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 1月28日的资金流向数据方面，主力资金净流出1034.32万元，占总成交额6.89%，游资资金净流入 1325.0万元，占总成交额8.82%，散户资金净流出290.68万元，占总成交额1.94%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近5日资金流向一览见下表： 心脉医疗2025年三季报显示，前三季度公司主营收入10.15亿元，同比上升4 ...

上海微创心脉医疗科技（集团）股份有限公司于2026年1月19日召开第三届董事会第十二次会议，审议 通过使用不超过人民币100,000万元的暂时闲置募集资金进行现金管理，投资安全性高、流动性好的产 品，包括结构性存款、通知存款、定期存款、大额存单、收益凭证等，使用期限为自董事会审议通过之 日起12个月内，资金可滚动使用。该事项无需提交股东大会审议。公司承诺不影响募集资金投资计划正 常进行，所获收益将用于补足募投项目资金不足及日常经营流动资金。 截至2026年1月23日收盘，心脉医疗（688016）报收于98.1元，较上周的97.98元上涨0.12%。本周，心 脉医疗1月23日盘中最高价报98.67元。1月20日盘中最低价报95.37元。心脉医疗当前最新总市值120.92 亿元，在医疗器械板块市值排名30/127，在两市A股市值排名1779/5182。 本周关注点 公司公告汇总：心脉医疗拟使用不超过10亿元暂时闲置募集资金进行现金管理。 公司公告汇总 心脉医疗：关于使用部分暂时闲置募集资金进行现金管理的公告 中国国际金融股份有限公司关于上海微创心脉医疗科技（集团）股份有限公司使用部分暂时闲置募集资 金进行现金管理 ...

Core Viewpoint - The sixth batch of national organized high-value medical consumables centralized procurement results have been announced, including 12 types of medical consumables, with execution expected around May 2026. The long-term growth potential of the high-value consumables sector is viewed positively due to the continuous increase in surgical and diagnostic volumes driven by aging populations and gradual import substitution [1]. Group 1: Event Details - On January 13, the results of the sixth batch of national organized high-value medical consumables centralized procurement were announced in Tianjin, involving 12 types of medical consumables, with 496 products from 227 companies bidding and 440 products from 202 companies winning [1]. - The procurement includes drug-coated balloons and urological intervention consumables, with a high selection ratio for the bidding products [2]. Group 2: Selection Process Optimization - The selection rules have been optimized to ensure that clinically recognized and capable products are chosen, stabilizing clinical usage [3]. - For differentiated products with certain functional innovations, a pricing coefficient based on clinical value has been established to reflect price differences reasonably [3]. - The lowest price is not the sole criterion for selection; if the lowest price is excessively low, a control benchmark of 65% of the average entry price is applied [3]. Group 3: Related Listed Companies - Companies related to coronary drug balloons include Lepu Medical, Blue Sail Medical, and MicroPort Medical [4]. - For peripheral drug balloons, companies such as Xianruida Medical-B, Gree创通桥, Xinmai Medical, and Lepu Medical are involved [4]. - In the urological intervention category, companies like Weili Medical and Weigao Group have all won bids, with examples of winning prices showing moderate reductions compared to earlier procurements [4].

Core Viewpoint - The recent CE MDR certification of the Talos/通天眼直管型支架 by 心脉医疗 signifies compliance with stringent EU medical device standards, enhancing the company's product portfolio in the European market [1]. Group 1 - 心脉医疗's Talos/通天眼直管型胸主动脉覆膜支架系统 has received CE MDR certification [1]. - The certification indicates that the product meets the rigorous standards set by the European Union for medical devices [1]. - This development further enriches and completes 心脉医疗's product offerings in the European market [1].

Core Viewpoint - The company, Xinmai Medical, has received CE MDR certification for its Talos®/Tongtian Eye™ straight tube thoracic aortic stent system, indicating compliance with strict EU medical device standards and enhancing its product portfolio in the European market [1]. Group 1 - The Talos®/Tongtian Eye™ straight tube stent system has been certified under the EU Medical Device Regulation (EU 2017/745) [1]. - This certification signifies that the product meets the rigorous standards set by the European Union for medical devices [1]. - The approval further enriches and completes Xinmai Medical's product offerings in the European market [1].